

Trastuzumab deruxtecan DESTINY-Breast04

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Trastuzumab deruxtecan DESTINY-Breast04

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Therapeutic Indication: Treatment of patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy  
 Experimental Arm: Trastuzumab deruxtecan  
 Control Arm: Physician's ChT choice (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel)



